Dr. Philip Robinson: Osteoarthritis and Inflammation
#GAMECHANGER. Failure of RA guidelines. 67% of MTX mono fail. Combo DMARDs or scMTX is better #acr17 @rheumnow #443 pic.twitter.com/q4P0fk460V
— Janet (@Janetbirdope) November 8, 2017
No difference in lung safety of Abatacept and TNFI and one study of more ILD with IFX vs ABA #137. #acr17 @rheumnow #526 pic.twitter.com/ugYBF7THKa
— Janet (@Janetbirdope) November 8, 2017
#ACR17 Rheumatology Roundup.Cush #11L biologics #2 CA; #1175 biologics infants; #141 Refractory RA; #1885 Epi of AOSD; #200 Gout Telemedicine ; #885 Voclosporin SLE GN. AKavanaugh #271 CD318; #1205 XRT OA? #661 Entheses; #1112 Pred Gout; #541 SIE; #2031 EMR labs; #144 MVA RA
— Dr. John Cush (@RheumNow) November 8, 2017
Rheum Rockstars playing to a packed house! Thanks @RheumNow and Dr. K you are a highlight of #ACR17 #RheumRoundUp pic.twitter.com/8MpdYgdutV
— Donna Hoyne (@donna_hoyne) November 8, 2017
#GAMECHANGER. Switching to a biosimilar in British registry shows no attenuation. #acr17 @rheumnow #2439 pic.twitter.com/w4qWCFpxic
— Janet (@Janetbirdope) November 8, 2017
Dr. Janet Pope: Interstitial Lung Disease and RA
Dr. Len Calabrese: Herpes Zoster
Dr. Julio Gonzalez: Radiographic Progression in Psoriatic Arthritis
Ustekinumab shows clinical benefit in SLE – SRI-4 response at Wk 24 was significantly better than placebo (∆ 29%) #ACR17 late breaking abstracts https://t.co/Q1cLdTjhWv
— Hector Chinoy (@drhectorchinoy) November 8, 2017
Dr. Philip Mease: FUTURE 5 Study
Dr. Paul Sufka: Pregnancy and Treatment
Dr. Jack Cush and Dr. Pete Salzmann (Eli Lilly and Company): Pain as a Differentiator
Improvement and steroid reduction in CANDLE / SAVI patients treated with baricitinib @RheumNow #ACR17 #2758
— Ian N Bruce (@Lupusdoc) November 7, 2017
#GAMECHANGER. If not responding to tociluzimab in RA you can respond to switch to 200 mg sarilab #acr17 @rheumnow #2468 pic.twitter.com/SwinP50HT3
— Janet (@Janetbirdope) November 7, 2017
Dr. Julio Gonzalez: Psoriatic Arthritis and AS
Addition of Steroid Rx to bDMARDs increases risk of post op infections. Effect dose depended #ACR17 #2755 @RheumNow pic.twitter.com/gELV2IriLc
— Olga Petryna (@DrPetryna) November 7, 2017
New Jak-1 selective inhibitor ABT-494 doesn’t look too bad #ACR17 @RheumNow pic.twitter.com/sAHVqJr31a
— Philip Robinson (@philipcrobinson) November 7, 2017
No increased risk of second malignancy in RA patients on biologics. #ACR17 @RheumNow #11L pic.twitter.com/YUfehZgzg8
— Dr. Paul Sufka (@psufka) November 7, 2017
Plenary #2754 tailored RTX based on +ANCA +CD19 B cells performed as well as scheduled RTX for AAV #ACR17 @rheumnow
— k dao (@KDAO2011) November 7, 2017
Serious infections in RA more associated with disease activity than DMARDs/biologics. #ACR17 @RheumNow #2410 pic.twitter.com/rq050WvnPJ
— Dr. Paul Sufka (@psufka) November 7, 2017
#16L #acr17 no risk of DVTorPE w/Tofa from RTC trials analysis. IRs comparable to #corona data for Tofa&cDMARDs @RheumNow pic.twitter.com/7Z2LclfE5m
— Olga Petryna (@DrPetryna) November 7, 2017
Effect of live HZ vaccine in MTX-IR w/RA getting tofa or ADA +/- MTX: well-tolerated, higher HZ rates in tofa+MTX #2393 #ACR17 @RheumNow
— Cassandra Calabrese (@CCalabreseDO) November 7, 2017
Danish registry: no increase risk of 2nd malignancy on biologics #11L #ACR17 @rheumnow
— k dao (@KDAO2011) November 7, 2017
#2453 #acr17 no difference in disease activity&PRO with ADA after MTX d/c at 6mo:LDA 42%ADAvs40%ADA+MTX @RheumNow pic.twitter.com/EtxpmVAQyL
— Olga Petryna (@DrPetryna) November 7, 2017
FUTURE5: Cosentyx clinically&radiofraph superior toPBO. mTSS non-progression 88%Cosentyx vs73% PBO #L17 #acr17 @RheumNow pic.twitter.com/7WI592W3s9
— Olga Petryna (@DrPetryna) November 7, 2017
Dr. Mease presenting late breaking abstract 17L on secukinumab and delaying radiographic progression in PsA. #ACR17 @rheumnow pic.twitter.com/jhuiT97P2i
— Dr. Rachel Tate (@uptoTate) November 7, 2017
R. Fleischmann regarding biosimilars, “there are not savings for the patient” @RheumNow #ACR17 pic.twitter.com/qdwVqsV3Zq
— Cassandra Calabrese (@CCalabreseDO) November 7, 2017
The Great Debate at #ACR17. Detailed summary for those who missed it @RheumNow https://t.co/gV3haLAYLg
— Dr Irwin Lim (@_connectedcare) November 7, 2017
Dr. Philip Robinson: Fatigue and Activity
Dr. Janet Pope: Pre-op for Total Hip or Knee Replacements in RA
Dr. Olga Petryna: Cardiovascular Comorbidities
Dr. Janet Pope: JAK 2 Inhibitor Controversy
Dr. Ken Saag: Update on Gout Therapy
Dr. David Borenstein: Pain
I’m quoted in the @Medscape article: “Predicting Successful Biologic Tapering for RA Feasible” https://t.co/viE7x6u7jG
— Dr. Paul Sufka (@psufka) November 6, 2017
How many of your patients get an Rx for a biologic? See how you compare to #RISE providers. #ACR17 Sun 9-11, abstract 202 @RheumNow pic.twitter.com/IislGhcH8G
— D White (@WIRheum) November 4, 2017
Significant reduction in immunosuppression load on uveitis pts with long term ADA use.#ACR17 @RheumNow
#1115 pic.twitter.com/YM2HM0d9sz— Julio Gonzalez (@japaoli19) November 6, 2017
Tolerizing pegloticase regimen decreases infusion reactions in TRIPLE study #1141 #ACR17 @RheumNow @HealioRheum pic.twitter.com/yFHQMAmozK
— Cassandra Calabrese (@CCalabreseDO) November 6, 2017
Inflammatory arthritis 1 day after nivolumab in pt w/remote +ACPA. Checkpoint inhibitors triggering autoimmunity? @RheumNow #ACR17 pic.twitter.com/OIUSOhAEf7
— Cassandra Calabrese (@CCalabreseDO) November 6, 2017
Cosentyx significantly improves ACR scores in PsA up to wk156, better in high CRP group #1523 #ACR17 @RheumNow pic.twitter.com/KgLIL74jKg
— Olga Petryna (@DrPetryna) November 6, 2017
Treatment of IRAEs has really been steroids & a few other Dmards #ACR17 @rheumnow pic.twitter.com/mzHoYHAPRt
— Dr Irwin Lim (@_connectedcare) November 5, 2017
Novel anti-CD40 CFZ533 improves ESSDAI and PG scores (ΔESSDAI=5.64)in phase 2a sjogren’s trial #ACR17 #1784 @RheumNow pic.twitter.com/vxx5rIvb4K
— Olga Petryna (@DrPetryna) November 6, 2017
RT @RheumNow: Risk of 2nd (recurrence) cancer after a 1st cancer is not increased with biologic use. #ACR17 Abs 11L pic.twitter.com/GMQVyXxZEh
— Dr Irwin Lim (@_connectedcare) November 6, 2017
#Biologic use during pregnancy may not increase opportunistic infection risk in infants. Press release: https://t.co/VCkbXno65Q #ACR17
— AmerCollRheumatology (@ACRheum) November 6, 2017
Novel Anti-CD40 monoclonal ab CFZ533 potential benefit in Sjogren's Syndrome. #ACR17 @RheumNow #1784 https://t.co/sehIStKFM1
— Dr. Rachel Tate (@DrRachelTate) November 6, 2017
FDA challenges in assessing safety of new drugs (aka:why it takes so long to get a drug approved) #ACR17 @rheumnow pic.twitter.com/5OdlbDToP3
— k dao (@KDAO2011) November 6, 2017
Here’s a list of other biologics being trialed in GCA. An exciting time #acr17 @RheumNow pic.twitter.com/nqNtRHSSni
— Dr Irwin Lim (@_connectedcare) November 6, 2017